当前位置: X-MOL 学术Annu. Rev. Cancer Biol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Engineering T Cells to Treat Cancer: The Convergence of Immuno-Oncology and Synthetic Biology
Annual Review of Cancer Biology ( IF 4.7 ) Pub Date : 2020-03-09 , DOI: 10.1146/annurev-cancerbio-030419-033657
Joseph H. Choe 1 , Jasper Z. Williams 1 , Wendell A. Lim 1
Affiliation  

T cells engineered to recognize and kill tumor cells have emerged as powerful agents for combating cancer. Nonetheless, our ability to engineer T cells remains relatively primitive. Aside from CAR T cells for treating B cell malignancies, most T cell therapies are risky, toxic, and often ineffective, especially those that target solid cancers. To fulfill the promise of cell-based therapies, we must transform cell engineering into a systematic and predictable science by applying the principles and tools of synthetic biology. Synthetic biology uses a hierarchical approach—assembling sets of modular molecular parts that can be combined into larger circuits and systems that perform defined target tasks. We outline the toolkit of synthetic modules that are needed to overcome the challenges of solid cancers, progress in building these components, and how these modules could be used to reliably engineer more effective and precise T cell therapies.

中文翻译:


工程化T细胞治疗癌症:免疫肿瘤学与合成生物学的融合

设计用于识别和杀死肿瘤细胞的T细胞已成为对抗癌症的强大药物。尽管如此,我们改造T细胞的能力仍然相对原始。除了用于治疗B细胞恶性肿瘤的CAR T细胞外,大多数T细胞疗法都是危险,有毒且通常无效的疗法,尤其是针对实体癌的疗法。为了实现基于细胞的疗法的前景,我们必须通过应用合成生物学的原理和工具,将细胞工程改造成系统且可预测的科学。合成生物学使用分级方法-组装模块化分子部分的集合,这些部分可以组合为执行定义的目标任务的更大的电路和系统。我们概述了合成模块所需的工具包,这些模块可克服实体癌症的挑战,在构建这些组件方面取得的进展,

更新日期:2020-03-09
down
wechat
bug